

Supplementary Table 1. Characteristics of the patient cohort and laboratory data

Patient ID	Age (years)	Gender	HCV genotype	Fibrosis stage (METAVIR)	Previous therapy	Response to previous therapy	Therapy	Length of therapy (weeks)	Baseline									End-of-therapy						Follow-up					
									MFAP4 (U/mL)	Fibroscan (kPa)	Viral load (U/mL)	GOT/AST (U/L)	GPT/ALT (U/L)	Platelets (x1,000/ μ L)	APRI	Albumin (proportion)	FIB-4	MFAP4 (U/mL)	Viral load (U/mL)	GOT/AST (U/L)	GPT/ALT (U/L)	Platelets (x1,000/ μ L)	APRI	Albumin (proportion)	FIB-4	MFAP4 (U/mL)	Viral load (U/mL)	Outcome	
1	66	W	1a	F1	PEG/RBV	NR	SOF, DCV	24	37.4	11.6	919	62	63	143	1.24	4.2	0.45	44	0	16	21	138	0.33	4.5	0.36	33	0	SVR	
2	47	M	1a	-	Naïve	-	SOF, RBV	24	68.6	48.0	79	40	23	114	0.7	3.2	0.73	69.1	0	23	10	120	0.38	3.3	0.92	53.6	0	SVR	
3	61	M	4	-	PEG/RBV	T, HCC	SOF, RBV	24	49.1	-	331,000	173	162	97	3.57	3.7	0.67	43.6	0	46	37	121	0.76	4	0.63	11.8	0	SVR	
4	58	W	2	F1-F2	Naïve	-	SOF, RBV	12	38.9	10.6	1,560,000	118	197	187	1.8	4.2	0.18	37.8	0	23	15	247	0.27	4.4	0.35	30	0	SVR	
5	34	W	2a/c	-	Naïve	-	SOF, RBV	12	17.2	-	5,760	40	66	191	0.6	4.7	0.10	15	0	19	9	215	0.25	-	0.32	17.4	0	SVR	
6	68	M	1a	F4	Albuphosphatidylcholin/RBV	NR	SOF, RBV	48	41.4	-	312	73	23	75	1.95	2.5	2.88	47	0	42	11	112	0.75	3.5	2.32	45.9	0	SVR	
7	60	M	2b	-	PEG/RBV	NR, SE	SOF, RBV	12	25.5	8.0	1,340,000	98	250	223	0.88	4.6	0.10	16.9	0	22	18	262	0.17	4.6	0.28	7.4	0	SVR	
8	59	M	2	-	Naïve	-	SOF, RBV	12	12.3	-	5,820,000	35	60	195	0.36	-	0.18	12.9	0	26	26	273	0.19	4.6	0.22	8.1	0	SVR	
9	59	W	2b	F1-F2	Naïve	-	SOF, RBV	12	39.1	6.8	3,620,000	166	257	312	1.52	4.6	0.12	30.6	0	21	13	299	0.2	4.3	0.32	24.4	0	SVR	
10	47	M	2a/c	F2	PEG/RBV	REL	SOF, RBV	12	34.3	14.0	1,490,000	36	59	119	0.61	4.6	0.24	32.3	0	27	26	167	0.32	4.6	0.29	20.1	0	SVR	
11	53	M	2	-	Alisporivir/RBV	REL	SOF, RBV	12	11.3	4.4	422,000	31	41	227	0.27	4.2	0.18	11.1	0	15	16	276	0.11	-	0.18	10.3	0	SVR	
12	52	M	2b	-	Naïve	-	SOF, RBV	12	8	5.6	94	47	66	260	0.36	4.7	0.14	18.8	0	20	17	265	0.15	4.7	0.23	13.1	0	SVR	
13	56	M	2b	-	Naïve	-	SOF, RBV	12	29.2	-	171,000	55	62	79	1.39	4.4	0.63	56.5	0	36	40	86	0.84	-	0.59	35.2	0	SVR	
14	60	M	2	-	Naïve	-	SOF, RBV	12	15.7	-	197	80	127	248	0.65	4.5	0.15	7.3	0	20	13	422	0.09	4.4	0.22	8.2	0	SVR	
15	57	M	2a/c	-	Naïve	-	SOF, RBV	12	13.1	-	5,290	52	112	276	0.38	-	0.10	10.8	0	27	20	275	0.2	4.5	0.28	10.1	-	SVR	
16	47	M	2a/c	-	PEG/RBV	REL	SOF, RBV	12	14.4	7.6	5,970,000	35	70	159	0.44	4.8	0.14	24	0	24	28	230	0.21	5	0.17	19.2	0	SVR	
17	56	W	2	-	Naïve	-	SOF, RBV	12	13.1	-	1,560,000	33	28	184	0.51	-	0.35	15	0	20	10	324	0.18	-	0.34	17.5	0	SVR	
18	54	W	2	F2	IFN/RBV	REL	SOF, RBV	12	17.1	8.8	495	47	44	193	0.7	-	0.30	25.9	0	21	15	225	0.27	4	0.34	15.9	0	SVR	
19	47	M	2a/c	-	Naïve	-	SOF, RBV	12	31.1	-	10,500	62	148	196	0.63	4.6	0.10	36.9	0	19	28	267	0.14	4.8	0.12	21.8	0	SVR	
20	46	W	2	-	Naïve	-	SOF, RBV	12	11.7	-	3,430,000	20	18	254	0.22	4.2	0.20	17.2	0	23	18	296	0.22	-	0.20	14.6	0	SVR	
21	20	M	3a	F0-F1	PEG/RBV	SE	SOF, RBV	24	7.1	6.6	970	32	41	220	0.29	4.8	0.07	12	0	21	12	205	0.2	4.4	0.16	4.6	0	SVR	
22	55	M	4	-	PEG/RBV, IFN/RBV	NR	SOF, RBV, DCV	24	31.4	-	632,000	70	66	76	1.84	3.6	0.75	41.3	0	51	40	75	1.36	4	0.92	33.5	0	SVR	
23	39	M	1a	-	-	-	SOF, RBV, DCV	24	54.4	-	6,040,000	237	97	49	9.67	3.2	1.94	42.8	-	-	-	-	-	-	-	-	23.4	0	SVR
24	37	M	1b	-	IFN/RBV, PEG/RBV, TVR	NR, T, SE	SOF, RBV, DCV	24	58.8	-	166,000	84	44	74	2.27	-	0.95	33.3	0	64	34	88	1.45	3.5	0.79	41.6	0	SVR	
25	58	M	4	-	PEG/RBV	T, SE	SOF, RBV, DCV	24	99.7	-	1,510,000	111	82	81	2.74	3.2	0.95	43.7	0	29	29	112	0.52	3.8	0.51	24.1	0	SVR	
26	76	M	1b	-	PEG/RBV	REL	SOF, RBV, DCV	12	21	-	2,610,000	35	34	131	0.53	4.4	0.60	15	0	31	19	169	0.37	4.6	0.73	11.8	0	SVR	
27	59	W	1b	F4	IFN/RBV, PEG/RBV	NR, SE	SOF, RBV, DCV	24	132.4	-	237,000	143	91	70	5.84	2.4	1.32	97	0	49	23	90	1.56	2.7	1.40	80.6	0	SVR	
28	63	M	1b	F4	PEG/RBV, PEG/RBV, TVR	NR, REL	SOF, SMV	12	99.1	8.8	1,920,000	80	92	108	1.48	4.4	0.50	65.6	0	26	31	152	0.34	4.5	0.34	43.6	0	SVR	

Supplementary Table 1. Continued

Patient ID	Age (years)	Gender	HCV genotype	Fibrosis stage (METAVIR)	Previous therapy	Response to previous therapy	Therapy	Length of therapy (weeks)	Baseline									End-of-therapy						Follow-up				
									MFAP4 (U/mL)	Fibroscan (kPa)	Viral load (U/mL)	GOT/AST (U/L)	GPT/ALT (U/L)	Platelets (x1,000/ μ L)	APRI	Albumin (proportion)	FIB-4	MFAP4 (U/mL)	Viral load (U/mL)	GOT/AST (U/L)	GPT/ALT (U/L)	Platelets (x1,000/ μ L)	APRI	Albumin (proportion)	FIB-4	MFAP4 (U/mL)	Viral load (U/mL)	Outcome
29	50	M	1a	F4	IFN/RBV, TVR/PEG/R	NR, BT	SOF, SMV	12	45.6	35.0	119	77	56	116	1.33	-	0.58	57.3	0	40	33	109	0.73	4.3	0.54	56.8	0	SVR
30	59	M	1a/b	F3	IFN/RBV, PEG/RBV/TVR	REL, NR	SOF, SMV	12	22.8	10.1	297,000	37	46	238	0.31	4.5	0.20	179	0	20	19	218	0.18	4.4	0.28	13.2	0	SVR
31	77	M	1b	F4	PEG/RBV	REL	SOF, SMV	12	27.1	21.3	82	23	20	558	0.08	4.4	0.16	21.8	-	21	15	616	0.07	4.6	0.18	20.8	0	SVR
32	48	M	1b	F4	PEG/RBV	REL	SOF, SMV	12	86.5	21.0	889,000	87	68	53	3.28	3.3	1.13	204.4	0	191	100	35	10.91	2.8	2.56	119.9	0	SVR
33	59	M	1a	-	PEG/RBV	BT	SOF, SMV	12	12.4	-	3,340,000	33	69	335	0.2	4.9	0.08	10.5	0	19	26	334	0.11	4.7	0.13	13.5	0	SVR
34	57	M	1a	-	-	-	SOF, SMV	12	32.5	7.8	1,190,000	79	157	173	0.91	4.3	0.17	27.1	-	-	-	-	-	-	-	13.4	0	SVR
35	59	M	1b	-	PEG/RBV, PEG/RBV/TVR	NR, REL	SOF, SMV	12	61.8	-	115,000	49	61	130	0.75	4	0.36	35.2	0	32	39	160	0.4	4.5	0.30	26.7	0	SVR
36	55	W	1b	F0-F1	PEG/RBV	REL	SOF, SMV	12	21.9	4.8	900	36	44	254	0.4	4.5	0.17	20.8	0	25	23	274	0.26	4.7	0.21	23.3	0	SVR
37	59	M	1a	F3	PEG/RBV	NR	SOF, SMV	12	33.6	9.9	9,190,000	60	89	236	0.51	4.3	0.17	16.5	0	25	23	269	0.19	4.6	0.24	36.4	0	SVR
38	49	M	1b	-	Naïve	-	SOF, SMV	12	70.6	-	1,140,000	122	235	85	2.87	3.9	0.29	50.3	0	25	30	113	0.44	4.3	0.35	43.5	0	SVR
39	82	M	1a/b	F4	-	-	SOF, SMV	12	55.6	8.6	4,490,000	136	133	146	1.86	4	0.57	28.3	0	37	25	151	0.49	4.3	0.80	23.1	0	SVR
40	54	M	1a	F4	PEG/RBV, PEG/RBV/TVR	NR, BT	SOF, SMV	12	53.5	21.1	292	117	131	61	3.84	4.4	0.79	44.4	0	64	110	60	2.13	4.9	0.52	38.4	0	SVR
41	33	W	1a	-	PEG/RBV	NR	SOF, SMV	12	50.8	20.5	3,090,000	157	123	83	5.4	3.7	0.49	31.1	0	29	17	96	0.86	4.2	0.57	31.6	0	SVR
42	57	W	1a	-	IFN/RBV	NR	SOF, SMV	12	70.7	48.0	991	143	45	54	7.57	3.9	3.30	63.8	0	37	11	74	1.43	4	2.55	66	0	SVR
43	71	W	1a	F3	Naïve	-	SOF, SMV	12	28.7	11.8	8,290,000	80	73	146	1.57	4	0.53	52.5	0	55	89	129	1.22	3.8	0.34	42.1	0	SVR
44	70	W	1a	F1-F1	PEG/RBV	REL	SOF, SMV	12	35.7	8.2	954,000	51	89	156	0.93	4.4	0.25	31.5	0	27	35	170	0.45	4.4	0.31	19	0	SVR
45	48	M	1a	-	PEG/RBV	T, PW	SOF, SMV	12	41.5	-	423,000	73	105	99	1.47	4.3	0.34	24.4	0	22	22	124	0.35	4.5	0.39	31	0	SVR
46	55	M	1b	F3	-	-	SOF, SMV	12	2.9	8.4	5,250,000	57	45	102	1.12	4.3	0.67	2.2	0	44	25	102	0.86	4.7	0.93	2.2	0	SVR
47	67	W	1b	F3	-	-	SOF, SMV	12	42.5	8.8	5,680,000	133	132	225	1.69	4.3	0.30	29.7	0	20	11	247	0.23	4.6	0.49	30.5	0	SVR
48	52	W	1b	F0	Naïve	-	SOF, SMV	12	12.2	7.8	656,000	35	41	202	0.5	4.7	0.22	9.9	0	22	18	199	0.32	4.7	0.32	7.1	0	SVR
49	60	M	1b	-	-	-	SOF, RBV, DCV	24	23	4.8	13,200,000	120	203	308	0.78	-	0.12	12.4	0	20	12	458	0.09	4.9	0.22	10.3	0	SVR
50	68	M	1	-	PEG/RBV, PEG/RBV/TVR	REL, SE	SOF, RBV, DCV	24	37.5	-	873,000	77	42	41	3.76	3.2	3.00	29.5	0	30	14	-	-	-	-	39.3	0	SVR

HCV, hepatitis C virus; METAVIR, scoring system for the assessment of hepatic fibrosis; MFAP4, microfibrillar-associated protein 4; GOT, glutamate oxaloacetate transaminase 1; AST, aspartate aminotransferase; GPT, glutamate pyruvate transaminase 1; ALT, alanine aminotransferase; APRI, AST to platelet ratio index; FIB-4, fibrosis-4 score; M, man; W, woman; F, fibrosis stage (according to METAVIR); PEG, pegylated interferon; RBV, ribavirin; IFN, interferon; TVR, telaprevir; R, responder; NR, non-responder; T, termination; HCC, hepatocellular carcinoma; SE, side effects; REL, relapse; BT, breakthrough; PW, patient's wish; SOF, sofosbuvir; DCV, daclatasvir; SMV, simeprevir; SVR, sustained virologic response to antiviral HCV therapy.